2Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study[J]. J Hepatol, 2009,50(6) : 1084-1092. DOI: 10. 1016/j. jhep. 2009. 01. 016.
3Buster EH, Hansen BE, Lau GK,et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa [J]. Gastroenterology, 2009, 137(6) :2002-2009. DOI: 10. 1053/j. gastro. 2009.08. 061.
4Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management [J]. J Hepatol, 2014,61(6) : 1407-1417. DOI: 10. 1016/i. jhep. 2014. 08.033.
6Fried MW, Piratvisuth T, Lau GK,et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B [J]. Hepatology, 2008,47 (2) : 428-434. DOI: 10. 1002/hep. 22065.
7Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection~ implications for antiviral therapy [J]. Gut, 2003,52(3), 416-419. DOI:10. 1136/gut. 52.3. 416.
8Cai Q, Chen F, Shao X, et al. Treatment of pegylated interferon- a2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation [J]. Antivir Thor, 2015,20(2) : 217-224. DOI: 10. 3851/IMP2832.
9Chen CC, Wang PC, Chang HW, etal. Safety and efficacy of two-step peginterferon a-2a treatment in patients of chronic hepatitis B with acute exacerbation [J]. J Viral Hepat, 2012, 19(3) :161-172. DOI:10. 1111/j. lg65-2893. 2011. 01469. x.
